Taxus Financial Statements From 2010 to 2025
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
Check Taxus Cardium financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Taxus Cardium's main balance sheet or income statement drivers, such as , as well as many indicators such as . Taxus financial statements analysis is a perfect complement when working with Taxus Cardium Valuation or Volatility modules.
Taxus |
Taxus Cardium Pharmaceuticals Company Shares Owned By Insiders Analysis
Taxus Cardium's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Taxus Cardium Shares Owned By Insiders | 0.21 % |
Most of Taxus Cardium's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taxus Cardium Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 0.21% of Taxus Cardium Pharmaceuticals are shares owned by insiders. This is 98.62% lower than that of the Biotechnology sector and 98.52% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 97.92% higher than that of the company.
Taxus Cardium Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Taxus Cardium's current stock value. Our valuation model uses many indicators to compare Taxus Cardium value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Taxus Cardium competition to find correlations between indicators driving Taxus Cardium's intrinsic value. More Info.Taxus Cardium Pharmaceuticals is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taxus Cardium's earnings, one of the primary drivers of an investment's value.About Taxus Cardium Financial Statements
Taxus Cardium investors utilize fundamental indicators, such as revenue or net income, to predict how Taxus Pink Sheet might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California. Taxus Cardium operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |